Cargando…
The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles
Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Nearly 50% of the patients who receive the most intensive treatment develop chemoresistant leukemia relapse. Although the leukemogenic events leading to relapse seem to differ between patients (i.e., regrowth from a clone detect...
Autores principales: | Aasebø, Elise, Berven, Frode S., Hovland, Randi, Døskeland, Stein Ove, Bruserud, Øystein, Selheim, Frode, Hernandez-Valladares, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352627/ https://www.ncbi.nlm.nih.gov/pubmed/32512867 http://dx.doi.org/10.3390/cancers12061466 |
Ejemplares similares
-
Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia
por: Aasebø, Elise, et al.
Publicado: (2020) -
Selecting Sample Preparation Workflows for Mass Spectrometry-Based Proteomic and Phosphoproteomic Analysis of Patient Samples with Acute Myeloid Leukemia
por: Hernandez-Valladares, Maria, et al.
Publicado: (2016) -
Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients
por: Hernandez-Valladares, Maria, et al.
Publicado: (2016) -
Preservation Method and Phosphate Buffered Saline Washing Affect the Acute Myeloid Leukemia Proteome
por: Wangen, Rebecca, et al.
Publicado: (2018) -
Proteomic Profiling of Primary Human Acute Myeloid Leukemia Cells Does Not Reflect Their Constitutive Release of Soluble Mediators
por: Aasebø, Elise, et al.
Publicado: (2018)